Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inmune Bio (INMB)
:INMB
INMB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.32 - $13.52
Previous CloseN/A
Volume114.20K
Average Volume (3M)497.56K
Market Cap
$201.55M
Enterprise Value$78.16M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Feb 27, 2025EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.18
Shares Outstanding22,172,451
10 Day Avg. Volume418,837
30 Day Avg. Volume497,562
Standard Deviation0.31
R-Squared0.10
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5009.92
Price to Cash Flow (P/CF)-7.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit504.27
Enterprise Value/Ebitda-2.56
Forecast
1Y Price Target
$23.40Price Target Upside157.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Inmune Bio News
PremiumCompany Announcements
Inmune Bio Secures License Agreement for CORDStrom Data---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe ongoing Phase 2 study in early/mild Alzheimer's disease patients is on track for complete enrollment, with topline data expected to be a significant catalyst for INMB shares.
Market OpportunityRecessive dystrophic epidermolysis bullosa (RDEB) could represent a $1B opportunity with potential for premium pricing.
Regulatory SupportThe FDA has indicated during a Type C meeting that the data from the study could support a filing.
Bears Say
Endpoint NoveltyOn the regulatory front, the EMACC endpoint correlates with the gold standard CDR-SB endpoint, which should help the FDA crosswalk the readout of the relatively novel primary EMACC endpoint.
Financial ConcernsINmune announced a $13M equity financing, which should extend the runway through the P2 data.
Trial ComplexityThe INmune blinded interim data is showing stat-sig correlation between EMACC and CDR, EMACC reliability, and EMACC differentiation in patients with different CDR ratings.
---
Ownership Overview
20.40% Insiders
4.74% Mutual Funds
7.55% Other Institutional Investors
61.63% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $4.32 and its highest was $13.52 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $201.55M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is Feb 27, 2025 which is in 5 days.
How were Inmune Bio’s earnings last quarter?
Inmune Bio released its earnings results on Oct 31, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.507 by -$0.093.
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate is -0.56.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 22,172,451 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Inmune Bio reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.507. Following the earnings report the stock price went up 3.248%.
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
---
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.40 (157.43% Upside)
$23.40 (157.43% Upside)
Blogger Sentiment
Neutral
INMB Sentiment 50%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.66%
12-Months-Change
Fundamentals
Return on Equity
-98.97%
Trailing 12-Months
Asset Growth
-15.82%
Trailing 12-Months
Company Description
Inmune Bio
Inmune Bio, Inc. is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.
---
INMB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, with significant achievements in clinical trial progress and financial stability outweighing the increased net loss and R&D expenses. The company's strategic focus on advancing its Alzheimer's and cancer programs shows promise for future developments.Read More>---
INMB Stock 12 Month Forecast
Average Price Target
$23.40
▲(157.43% Upside)
Technical Analysis
Cassava Sciences
―
Axon Enterprise
―
Aurinia Pharmaceuticals
―
Anavex Life Sciences
―
Annovis Bio
―
Best Analysts Covering INMB
1 Year
1 Year Success Rate
8/14 ratings generated profit
1 Year Average Return
+8.39%
reiterated a buy rating 10 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +8.39% per trade.
---